Liraglutide is indicated as an adjunct to a reduced-energy diet and increased physical activity for weight loss management in adults with a BMI 30 kg/m 2 or BMI of 27 kg/m 2 and at least one weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia, or obstructive sleep apnoea
Our findings underscore the possibility for wider applications for these medications but also highlight important risks that should be carefully monitored in people taking these drugs.
For those building muscle while on GLP-1 medications , the increased protein demands create another reason to prioritize hydration
Patients often report feeling hungrier between meals, experiencing more frequent food cravings, and requiring larger portions to feel satisfied
Psychiatric disorders and type 2 diabetes mellitus: a bidirectional mendelian randomization
Critical adjustment period Early months require guidance for dosing, tolerance, & progress for long-term success 2x Longer on therapy Ongoing support keeps patients on GLP-1s 2x longer, maximizing long-term benefits 9+ Systems affected GLP-1s influence brain, heart, kidney, & more